The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
963
December 8, 1995
View Complete Issue         Table of Contents 2019 
Riluzole for Amyotrophic Lateral Sclerosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Riluzole for Amyotrophic Lateral Sclerosis
December 8, 1995 (Issue: 963)
The US Food and Drug Administration (FDA) has approved 'early access' use of riluzole (Rilutek - Rh ne-Poulenc Rorer) for treatment of amyotrophic lateral sclerosis (ALS). is the first drug to become available for treatment of this condition. The...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Riluzole for Amyotrophic Lateral Sclerosis
Article code: 963a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.